Payment overview · 2025
General Payments
$4,026.87
151 reported records · 22 companies
Healthcare provider profile · identity verified
Jason Bryant Goolsby, DO
Allopathic & Osteopathic Physicians|Family Medicine · BROWNSVILLE, TN · NPI 1801925938
Verified facts
What the public records show
CMS Open Payments records show Jason Bryant Goolsby, DO received $4,026.87 in general payments during 2025 across 151 reported records.
Biogen, Inc. accounted for 34.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Rybelsus, Skyclarys, Trelegy Ellipta, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Kerendia by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SKYCLARYS as an associated drug or biological on 3512 records involving 2165 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Skyclarys by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Biogen, Inc. | Unresolved — no canonical attribution shown | $1,367.39 | 34.0% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $453.34 | 11.3% | 18 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $417.32 | 10.4% | 23 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $294.69 | 7.3% | 15 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $209.93 | 5.2% | 11 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $170.90 | 4.2% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $166.61 | 4.1% | 12 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $161.69 | 4.0% | 11 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $154.71 | 3.8% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $143.74 | 3.6% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $74.26 | 1.8% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $68.61 | 1.7% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $68.53 | 1.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $64.85 | 1.6% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $42.51 | 1.1% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $39.13 | 1.0% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.68 | 0.7% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $25.96 | 0.6% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $23.41 | 0.6% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $21.74 | 0.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.50 | 0.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.37 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,738.87 | 150 |
| Consulting Fee | $1,288.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $272.14 | 8 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $237.76 | 12 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $235.04 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $218.42 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $186.51 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $182.32 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $182.32 | 9 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $170.90 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $169.72 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $166.61 | 12 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $161.69 | 11 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $154.71 | 10 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $143.74 | 10 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $124.97 | 7 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $99.01 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $81.64 | 5 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $79.39 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $68.53 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $67.60 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $64.85 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $64.85 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $48.49 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $46.43 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $46.43 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $43.52 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $26.68 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $25.96 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $25.09 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $23.41 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $21.74 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $17.31 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $9.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 138 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 144 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 163 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 55 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 73 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 66 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SKYCLARYS skyclarys |
2025 | Skyclarys | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 123 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
55 | 25 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
144 | 40 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | SKYCLARYS open payments reported associated product |
CMS Open Payments — General Payments 3512 supporting records · 2165 recipient NPIs · example record 1208299709 |
Skyclarys · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
163 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
123 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
163 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
73 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
52 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
66 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
138 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 738 | 208 |
| Amlodipine Besylate | Amlodipine Besylate | 507 | 148 |
| Furosemide | Furosemide | 398 | 121 |
| Omeprazole | Omeprazole | 362 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 357 | 85 |
| Losartan Potassium | Losartan Potassium | 349 | 99 |
| Lisinopril | Lisinopril | 303 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 285 | 77 |
| Meloxicam | Meloxicam | 284 | 76 |
| Potassium Chloride | Potassium Chloride | 258 | 83 |
| Famotidine | Famotidine | 240 | 69 |
| Simvastatin | Simvastatin | 226 | 62 |
| Tramadol Hcl | Tramadol Hcl | 216 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 215 | 62 |
| Alprazolam | Alprazolam | 211 | 39 |
| Gabapentin | Gabapentin | 211 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 207 | 54 |
| Pregabalin | Pregabalin | 204 | 35 |
| Metformin Hcl | Metformin Hcl | 194 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 192 | 58 |
| Allopurinol | Allopurinol | 185 | 57 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 183 | 51 |
| Carvedilol | Carvedilol | 176 | 62 |
| Jardiance | Empagliflozin | 163 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 160 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 157 | 48 |
| Pioglitazone Hcl | Pioglitazone Hcl | 155 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 152 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 144 | 37 |
| Farxiga | Dapagliflozin Propanediol | 144 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 142 | 40 |
| Eliquis | Apixaban | 138 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 132 | 32 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 123 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 112 | 49 |
| Trazodone Hcl | Trazodone Hcl | 112 | 37 |
| Prednisone | Prednisone | 104 | 71 |
| Zolpidem Tartrate | Zolpidem Tartrate | 104 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 99 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 96 | 26 |
| Methocarbamol | Methocarbamol | 91 | 46 |
| Sertraline Hcl | Sertraline Hcl | 89 | 27 |
| Celecoxib | Celecoxib | 83 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 81 | 27 |
| Buspirone Hcl | Buspirone Hcl | 80 | 17 |
| Memantine Hcl | Memantine Hcl | 80 | 17 |
| Metformin Hcl Er | Metformin Hcl | 79 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 76 | 64 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 73 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 73 | 27 |
| Mounjaro | Tirzepatide | 73 | 16 |
| Azithromycin | Azithromycin | 72 | 66 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 70 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 70 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 69 | 24 |
| Ozempic | Semaglutide | 66 | 15 |
| Clonazepam | Clonazepam | 65 | 11 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 63 | 19 |
| Fluconazole | Fluconazole | 63 | 39 |
| Quetiapine Fumarate | Quetiapine Fumarate | 63 | 22 |
| Spironolactone | Spironolactone | 59 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 57 | 16 |
| Ezetimibe | Ezetimibe | 56 | 15 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 56 | suppressed |
| Cefdinir | Cefdinir | 55 | 48 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 55 | 15 |
| Linzess | Linaclotide | 55 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 54 | 32 |
| Montelukast Sodium | Montelukast Sodium | 54 | 20 |
| Xarelto | Rivaroxaban | 54 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 51 |
| Entresto | Sacubitril/Valsartan | 52 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 50 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 48 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | 12 |
| Clonidine Hcl | Clonidine Hcl | 47 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 47 | 13 |
| Baclofen | Baclofen | 46 | 15 |
| Estradiol | Estradiol | 46 | suppressed |
| Nifedipine Er | Nifedipine | 46 | 13 |
| Meclizine Hcl | Meclizine Hcl | 45 | 18 |
| Mupirocin | Mupirocin | 44 | 30 |
| Methylprednisolone | Methylprednisolone | 42 | 38 |
| Atenolol | Atenolol | 41 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 40 | suppressed |
| Calcitriol | Calcitriol | 40 | suppressed |
| Belsomra | Suvorexant | 39 | suppressed |
| Lorazepam | Lorazepam | 39 | 15 |
| Glimepiride | Glimepiride | 38 | 12 |
| Lovastatin | Lovastatin | 37 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 32 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Repatha Sureclick | Evolocumab | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 29 |
| Finasteride | Finasteride | 34 | suppressed |
| Topiramate | Topiramate | 33 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 31 | suppressed |
| Trulicity | Dulaglutide | 31 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 22 |
| Levofloxacin | Levofloxacin | 29 | 25 |
| Trintellix | Vortioxetine Hydrobromide | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | 11 |
| Galantamine Hbr | Galantamine Hbr | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Naproxen | Naproxen | 25 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 23 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 23 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | 13 |
| Valsartan | Valsartan | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Kerendia | Finerenone | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Invokamet Xr | Canagliflozin/Metformin Hcl | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Prolia | Denosumab | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | 15 |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Phenytoin | Phenytoin | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Invokamet | Canagliflozin/Metformin Hcl | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | 12 |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | 11 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Skyclarys | Omaveloxolone | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,026.87 · 151 records | Biogen, Inc. | AIRSUPRA, AUSTEDO XR, Auvelity, BREZTRI, CAPLYTA, CREON, Doc Band, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, Korlym, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SKYCLARYS, Symbravo, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VIBERZI, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error